T cells have long held the title of the ideal immune cells for CAR therapy, but recent discoveries are opening new possibilities for other immune cells.
Artificial intelligence is helping researchers fill in critical gaps in medical treatment by identifying new drug targets for more precision medicine solutions.
Slight modifications to glycoproteins reveal critical insights into disease onset, state, and progression, making them a wellspring for biomarker discovery.
Antibodies that simultaneously target two distinct antigens overcome cancer therapy resistance by addressing antigenic diversity and diminished T cell action.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.